The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: A randomized placebo-controlled study

Bone

Volumn 36, Issue 2, 2005, Pages 358-364

  Leung, Jenny Y Y ^a   Ho, Andrew Y Y ^b   Ip, T P ^c   Lee, Gavin ^d   Kung, Annie W C ^b  

^a RUTTONJEE HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c TUNG WAH EASTERN HOSPITAL   (Hong Kong)

^d PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

BMD; Bone markers; Chinese; Risedronate

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CALCIUM CARBONATE; OSTEOCALCIN; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; ASIAN; BLOOD ANALYSIS; BONE DENSITY; BONE TURNOVER; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEMUR NECK; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIP; HONG KONG; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SPINE; STROKE; TREATMENT OUTCOME; URINALYSIS;

EID: 14144254635     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2004.10.014     Document Type: Article

References (28)

1. C. Cooper, G. Compion, and L.J. Melton Hip fractures in the elderly: a worldwide projection Osteoporos. Int. 2 1992 285 289
2. E.M. Lau, J.K. Lee, P. Suriwongpaisal, S.M. Saw, S. Das De, and A. Khir The incidence of hip fracture in four Asian countries: the Asian Osteoporosis Study (AOS) Osteoporos. Int. 12 3 2001 239 243
3. E.M. Lau, C. Cooper, S. Wickham Donnan, and D.J.P. Barker Hip fracture in Hong Kong and Britain Int. J. Epidemiol. 19 4 1990 1119 1121
4. E.M. Lau, H.H. Chan, J. Woo, F. Lin, D. Black, and M. Nevitt Normal ranges for vertebral height ratios and prevalence of vertebral fracture in Hong Kong Chinese: a comparison with American Caucasians J. Bone Miner. Res. 11 9 1996 1364 1368
5. J. Woo, S.C. Ho, L.M. Yu, J. Lau, and Y.K. Yuen Impact of chronic diseases on functional limitations in elderly Chinese aged 70 years and over: a cross sectional and longitudinal survey J. Gerontol. A Biol. Sci. Med. Sci. 53 2 1998 M102 M106
6. Writing Group for the Women' Health Initiative Risks and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 3 2002 321 333
7. G.W. Tang The climacteric of Chinese factory workers Mauritas 19 1994 177 182
8. S.T. Harris, N.B. Watts, H.K. Genant, C.D. McKeever, T. Hangartner, and M. Keller Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group JAMA 282 14 1999 1344 1352
9. M.R. McClung, P. Geusens, P.D. Miller, H. Zippel, W.G. Bensen, and C. Roux Effects of risedronate on the risk of hip fracture in elderly women N. Engl. J. Med. 344 5 2001 333 340
10. I. Fogelman for the BMD-MN Study Group Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational double-blind, placebo-controlled trial J. Clin. Endocrinol. Metab. 85 5 2000 1895 1900
11. A. Cranney, P. Tugwell, J. Adachi, B. Weaver, N. Zytaruk, A. Papaioannou the Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis Endocr. Rev. 23 4 2002 517 523
12. R. Civitelli, S. Gonnelli, F. Zacchei, S. Bigazzi, A. Vattimo, and L.V. Avioli Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment J. Clin. Invest. 82 1998 1268 1274
13. A.W.C. Kung, S.S.C. Yeung, and L.W. Chu The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study Calcif. Tissue Int. 67 2000 286 290
14. S.R. Cummings for the Fracture Intervention Trial Research Group Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures: results from Fracture Intervention Trial JAMA 280 24 1998 2077 2082
15. O. Johnell, W.H. Scheele, Y. Lu, J.Y. Reginster, A.G. Need, and E. Seeman Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis J. Clin. Endocrinol. Metab. 87 3 2002 985 992
16. S.T. Cummings, D.B. Karpf, F. Harris, H.K. Genant, K. Ensurd, and A.Z. LaC-roix Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs Am. J. Med. 112 2002 281 289
17. S. Sarkar, B.H. Mitlak, M. Wong, J. Stock, D.M. Black, and K.D. Harper Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J. Bone Miner. Res. 17 2002 1 10
18. Z. Li, M.P. Meredith, and M.S. Hoseyni A method to assess the proportion of treatment effect explained by a surrogate endpoint Stat. Med. 20 2001 3175 3188
19. R.D. Wasnich, and P.D. Miller Antifracture efficacy of antiresorptive agents are related to changes in bone density J. Clin. Endocrinol. Metab. 85 2000 231 236
20. M.C. Hochberg for the Fracture Intervention Trial Research Group Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with post-menopausal osteoporosis Arthritis Rheum. 42 1999 1246 1254
21. M.C. Hochberg, S. Greensapn, R.D. Wasnich, P. Miller, D.E. Thompson, and P.D. Ross Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents J. Clin. Endocrinol. Metab. 87 2002 1586 1592
22. N.H. Bjarasson, S. Sarkar, T. Duong, B. Mitlak, P.D. Delmas, and C. Christiansen Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis Osteoporos. Int. 12 2001 922 930
23. R. Eastell, I. Barton, R.A. Hannon, A. Chines, P. Garnero, and P.D. Delmas Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate J. Bone Miner. Res. 18 6 2003 1051 1056
24. D.C. Bauer, D.M. Black, P. Garnero, M. Hochberg, S.M. Oh, and D.L. Schneider Reduction in bone turnover predicts hip non-spine and vertebral fracture in alendronate treated women: the fracture intervention trial Osteoporos. Int. 13 2002 521
25. P. Gerdhem, K.K. Ivaska, S.L. Alatalo, J.M. Halleen, J. Hellman, and A. Isaksson Biochemical markers of bone metabolism and prediction of fracture in elderly women J. Bone Miner. Res. 19 2004 386 393
26. S. Sarkar, J.Y. Reginster, G.G. Crans, A. Diez-Perez, K.V. Pinette, and P.D. Delmas Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk J. Bone Miner. Res. 19 2004 394 401
27. M.J. Seibel, V. Naganathan, I. Barton, and A. Grauer Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate J. Bone Miner. Res. 19 2004 323 329
28. H. Taggart, M. Bolognese, R. Lindsay, M. Ettinger, H. Mulder, and R.G. Josse Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials Mayo Clin. Proc. 77 3 2002 262 270